期刊文献+

阿帕替尼联合紫杉醇二线治疗对晚期食管癌患者生存质量及miR-20a、HER-2蛋白表达的影响 被引量:2

Effects of apatinib combined with paclitaxel second-line therapy on the quality of life and the expression of miR-20a,HER-2 protein in patients with advanced esophageal cancer
下载PDF
导出
摘要 目的探讨阿帕替尼联合紫杉醇二线治疗对晚期食管癌患者生存质量及微小RNA-20a(miR-20a)、人表皮生长因子受体-2(HER-2)蛋白表达的影响。方法选择2018年1月至2020年1月收治的72例晚期食管癌患者,根据治疗方案不同将其分为对照组和观察组,各36例。对照组采用紫杉醇二线化疗方案,观察组在对照组基础上施加阿帕替尼。比较两组的治疗效果。结果治疗后,观察组的欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)各功能领域评分均高于对照组(P<0.05)。治疗后,观察组的癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原72-4(CA72-4)水平均低于对照组(P<0.05)。治疗后,观察组的miR-20a、HER-2蛋白表达水平均低于对照组(P<0.05)。结论阿帕替尼联合紫杉醇二线治疗晚期食管癌可提高患者的生存质量,降低肿瘤标志物水平,调节miR-20a、HER-2蛋白表达水平。 Objective To investigate the effects of apatinib combined with paclitaxel second-line therapy on the quality of life and the expression of microRNA-20a(miR-20a),human epithelial growth factor receptor-2(HER-2)protein in patients with advanced esophageal cancer.Methods A total of 72 patients with advanced esophageal cancer admitted from January 2018 to January 2020 were selected and divided into control group and observation group according to different treatment regimens,with 36 cases in each group.The control group was treated with paclitaxel second-line chemotherapy,and the observation group was treated with apatinib on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the scores of all functional areas of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(EORTC QLQ-C30)in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)and carbohydrate antigen 72-4(CA72-4)in the observation group were lower than those in the control group(P<0.05).After treatment,the expression levels of miR-20a and HER-2 protein in the observation group were lower than those in the control group(P<0.05).Conclusion Apatinib combined with paclitaxel in the second-line treatment of advanced esophageal cancer can improve the quality of life of patients,reduce the levels of tumor markers,and regulate the expression levels of miR-20a,HER-2 proteins.
作者 苏华 赵玉梅 陈静 蔡莉娜 吴树彪 SU Hua;ZHAO Yumei;CHEN Jing;CAI Lina;WU Shubiao(No.1 Ward of Oncology Department,the Lankao First Hospital,Kaifeng 475300;Gynecology and Obstetrics Department,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450003;Anesthesiology Department,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450003,China)
出处 《临床医学研究与实践》 2023年第7期56-58,共3页 Clinical Research and Practice
关键词 阿帕替尼 紫杉醇 晚期食管癌 apatinib paclitaxel advanced esophageal cancer
  • 相关文献

参考文献15

二级参考文献154

共引文献211

同被引文献25

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部